UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 10-Q

 

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the quarterly period ended SeptemberJune 30, 20222023

 

or

 

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the transition period from ______ to ______

 

Commission File Number 000-56157

 

Achison IncAntiaging Quantum Living Inc.

(Exact name of registrant as specified in its charter)

 

New York 47-2643986
(State or Other Jurisdiction (I.R.S. Employer
of Incorporation or Organization) Identification No.)

 

135-22 Northern Blvd.133-27 39th Ave, 2nd FlThs #PH2A

Flushing, NY 11354

(Address of Principal Executive Offices) (Zip Code)

 

(917)(929) 470-5393527-5382

(Registrant’s telephone number, including area code)

 

N/A

(Former name, former address and former fiscal year, if changed since last report)

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class Trading Symbol(s) Name of each exchange on which registered
Not applicable  Applicable Not applicable  Applicable Not applicable  Applicable

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filerAccelerated filer
Non-accelerated filerSmaller reporting company
  Emerging growth company

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No

 

As of November 11, 2022,August 14, 2023, the registrant had 29,995,000 shares of Class A common stock outstanding.

 

 

 

 

 

TABLE OF CONTENTS

 

  PAGE
   
 Note about Forward-Looking Statements3
   
 PART I - FINANCIAL INFORMATION 
Item 1Financial Statements4
 Balance Sheets as of June 30, 2023 (unaudited) and March 31, 2023
Item 1Financial Statements5
 Balance Sheets asStatements of SeptemberOperations for the three months ended June 30, 2023 and 2022 (unaudited) and March 31, 20226
 Statement of Operations (unaudited) for the three and six months ended September 30, 2022 and 20217
Statements of Changes in Stockholders’ Deficit (unaudited) for the three and six months ended SeptemberJune 30, 2023 and 2022 (unaudited)7
Statements of Cash Flows for the three months ended June 30, 2023 and 20212022 (unaudited)8
 Statements of Cash Flows (unaudited) for the six months ended September 30, 2022 and 20219
Notes to Unaudited Financial Statements109
Item 2Management’s Discussion and Analysis of Financial Condition and Results of Operation14
Item 3Quantitative and Qualitative Disclosures About Market Risk1615
Item 4Controls and Procedures16
   
 PART II - OTHER INFORMATION 
   
Item 1Legal Proceedings1716
Item 1ARisk Factors1716
Item 2Unregistered Sales of Equity Securities and Use of Proceeds1716
Item 3Defaults Upon Senior Securities1716
Item 4Mine Safety Disclosures1716
Item 5Other Information1716
Item 6Exhibits17
   
SIGNATURES18
EXHIBIT INDEX19

 

2

 

NOTE ABOUT FORWARD-LOOKING STATEMENTS

 

This Quarterly Reportquarterly report on Form 10-Q contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this Quarterly Reportquarterly report on Form 10-Q other than statements of historical fact, including statements regarding our future results of operations and financial position, our business strategy and plans, and our objectives for future operations, are forward-looking statements. The words “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” and similar expressions are intended to identify forward-looking statements. We have based these forward-looking statements largely on our current expectations and projections about future events and trends that we believe may affect our financial condition, results of operations, business strategy, short-term and long-term business operations and objectives, and financial needs. These forward-looking statements are subject to a number of risks, uncertainties and assumptions. Moreover, we operate in a very competitive and rapidly changing environment. New risks emerge from time to time. It is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements we may make. In light of these risks, uncertainties and assumptions, the future events and trends discussed in this Quarterly Reportquarterly report on Form 10-Q may not occur and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements.

 

We undertake no obligation to revise or publicly release the results of any revision to these forward-looking statements, except as required by law. Given these risks and uncertainties, readers are cautioned not to place undue reliance on such forward-looking statements.

 

Unless expressly indicated or the context requires otherwise, the terms “Achison,“Antiaging,“Company,“company,” “we,” “us,” and “our” in this document refer to AchisonAntiaging Quantum Living Inc, a New York corporation.

 

3

 

PART I – FINANCIAL INFORMATION

 

ITEM 1. FINANCIAL STATEMENTS

 

ACHISONANTIAGING QUANTUM LIVING INC

 

INDEX TO FINANCIAL STATEMENTS

 

Balance Sheets as of SeptemberJune 30, 20222023 (unaudited) and March 31, 202220235
  
Statements of Operations (unaudited) for the three and six months ended SeptemberJune 30, 2023 and 2022 and 2021(unaudited)6
  
Statements of Changes in Stockholders’ Deficit (unaudited) for the three and six months ended SeptemberJune 30, 2023 and 2022 and 2021(unaudited)7
  
Statements of Cash Flows (unaudited) for the sixthree months ended SeptemberJune 30, 2023 and 2022 and 2021(unaudited)8
  
Notes to Unaudited Financial Statements9 - 1013

 

4

 

ANTIAGING QUANTUM LIVING INC (FKA. ACHISON INC.INC)

BALANCE SHEETS

 

 2023  2023 
 September 30, March 31,  June 30, March 31, 
 2022  2022  2023  2023 
  (Unaudited)      (Unaudited)   
ASSETS                
Current assets                
Cash and cash equivalents $1,301  $14,269  $34,324  $354 
Prepaid expense  738   - 
Total current assets  1,301   14,269   35,062   354 
                
Furniture, net  697   854 
Equipment, net  462   540 
TOTAL ASSETS $1,998  $15,123  $35,524  $894 
                
LIABILITIES AND STOCKHOLDERS’ EQUITY        
LIABILITIES AND STOCKHOLDERS’ DEFICIT        
Current liabilities                
Accrued liabilities $4,302  $901 
Loan from shareholders  62,156   83,300 
Contract liabilities $3,200  $5,600   1,600   2,800 
Loan from a shareholder  70,900   59,000 
Total current liabilities  74,100   64,600   68,058   87,001 
                
TOTAL LIABILITIES  74,100   64,600   68,058   87,001 
                
COMMITMENTS AND CONTINGENCIES  -   -   -   - 
                
STOCKHOLDERS EQUITY        
Preferred stock: $0.001 par value, 20,000,000 shares authorized; no share issued and outstanding  -   - 
Class A Common stock, $0.001 par value, 100,000,000 authorized, 29,995,000 shares issued and outstanding as of September 30, 2022 and March 31, 2022  29,995   29,995 
STOCKHOLDERS’ DEFICIT        
Class A common stock, $0.001 par value, 30,000,000 authorized, 29,995,000 shares issued and outstanding  29,995   29,995 
Additional paid-in capital  160,230   160,230   243,530   160,230 
Accumulated deficit  (262,327)  (239,702)  (306,059)  (276,332)
TOTAL STOCKHOLDERS’ DEFICIT  (72,102)  (49,477)  (32,534)  (86,107)
TOTAL LIABILITIES AND STOCKHOLDERS’ DEFICIT $1,998  $15,123  $35,524  $894 

 

The accompanying notes are an integral part of these financial statements

 

5

 

ANTIAGING QUANTUM LIVING INC (FKA. ACHISON INC.INC)

UNAUDITED CONDENSED STATEMENTS OF OPERATIONS

(Unaudited)

 2022  2021  2022  2021  2023  2022 
 Three months ended Six months ended  Three months ended 
 September 30,  September 30,  June 30, 
 2022  2021  2022  2021  2023  2022 
Revenue $6,000  $1,800  $8,400  $3,600  $1,200  $2,400 
Cost of Revenue  -   600   -   600 
Gross profit  6,000   1,200   8,400   3,000   1,200   2,400 
                        
Operating expenses:                        
General and administrative  7,520   8,832   31,025   25,043   30,927   23,505 
Total operating expenses  7,520   8,832   31,025   25,043   30,927   23,505 
                        
Loss from operations  (1,520)  (7,632)  (22,625)  (22,043)  (29,727)  (21,105)
                        
Other income (expenses):                
Interest income  -   701   -   1,574 
Total other income (expenses), net  -   701   -   1,574 
                
Loss before income tax  (1,520)  (6,931)  (22,625)  (20,469)  (29,727)  (21,105)
Income tax expense  -   -   -   -   -   - 
                        
Net Loss $(1,520) $(6,931) $(22,625) $(20,469)
Net income (loss) $(29,727) $(21,105)
                        
Weighted average shares outstanding:                        
Basic and diluted  29,995,000   29,995,000   29,995,000   29,995,000 
Basic and Diluted  29,995,000   29,995,000 
                        
Loss per share attributable to common parent’s shareholders:                
Basic and diluted $(0.00) $(0.00) $(0.00) $(0.00)
Loss per share attributable to common stockholders:        
Basic and Diluted $(0.001) $(0.001)

 

The accompanying notes are an integral part of these financial statements

 

6

 

ANTIAGING QUANTUM LIVING INC (FKA. ACHISON INC.INC)

STATEMENTS OF CHANGES IN STOCKHOLDERS’ DEFICIT

(Unaudited)

                      
  Preferred Stock  Class A Common Stock  

Additional

Paid-in

  Accumulated    
  Shares  Amount  Shares  Amount  Capital  Deficit  Total 
Balances, March 31, 2022  -  $-   29,995,000  $29,995  $160,230  $(239,702) $(49,477)
Net loss  -   -   -   -   -   (21,105)  (21,105)
Balance, June 30, 2022  -   -   29,995,000   29,995   160,230   (260,807)  (70,582)
Net loss  -   -   -   -   -   (1,520)  (1,520)
Balances, September 30, 2022  -  $-   29,995,000  $29,995  $160,230  $(262,327) $(72,102)
  Shares  Amount  Capital  Deficit  Total 
  Class A Common Stock  

Additional

Paid-in

  Accumulated    
  Shares  Amount  Capital  Deficit  Total 
Balances, March 31, 2023  29,995,000  $29,995  $160,230  $(276,332) $(86,107)
Shareholder loan cancellation  -   -   83,300   -   83,300 
Net loss  -   -   -   (29,727)  (29,727)
Balances, June 30, 2023  29,995,000  $29,995  $243,530  $(306,509) $(32,534)

 

  Preferred Stock  Class A Common Stock  

Additional

Paid-in

  Accumulated    
  Shares  Amount  Shares  Amount  Capital  Deficit  Total 
                      
Balances, March 31, 2021  -  $-   29,995,000  $29,995  $160,230  $(196,266) $(6,041)
Net loss  -   -   -   -   -   (13,538)  (13,538)
Balance, June 30, 2021  -   -   29,995,00   29,995   160,230   (209,804)  (19,579)
Net loss  -   -   -   -   -   (6,931)  (6,931)
Balances, September 30, 2021  -  $-   29,995,000  $29,995  $160,230  $(216,735) $(26,510)

The accompanying notes are an integral part of these financial statements

7

ACHISON INC.

STATEMENTS OF CASH FLOWS

(Unaudited)

  2022  2021 
  For the six months ended
September 30,
 
  2022  2021 
       
Cash flows from operating activities:        
Net loss $(22,625) $(20,469)
Adjustments to reconcile net loss to net cash used in operating activities:        
Depreciation  157   32 
Changes in operating assets and liabilities:        
Accrued interest income on note receivable  -   (1,574)
Contract liabilities  (2,400)  1,200 
Net cash used in operating activities  (24,868)  (20,811)
         
Cash flows from financing activities:        
Proceeds from collection of notes receivables  -   52,437 
Purchase of property and equipment  -   (950)
Repayment of shareholder loan  11,900   - 
Net cash provided by financing activities  11,900   51,487 
         
Net (decrease) increase in cash  (12,968)  30,676 
Cash at beginning of period:  14,269   17,496 
Cash at end of period: $1,301  $48,172 
         
SUPPLEMENTARY DISCLOSURES OF CASH FLOW INFORMATION        
Interest paid $-  $- 
Income tax paid $-  $- 
  Class A Common Stock  

Additional

Paid-in

  Accumulated    
  Shares  Amount  Capital  Deficit  Total 
Balances, March 31, 2022  29,995,000  $29,995  $160,230  $(239,702) $(49,477)
Net loss  -   -   -   (21,105)  (21,105)
Balances, June 30, 2022  29,995,000  $29,995  $160,230  $(260,807) $(70,582)

 

The accompanying notes are an integral part of these financial statements

 

7

ANTIAGING QUANTUM LIVING INC (FKA. ACHISON INC)

UNAUDITED CONDENSED STATEMENTS OF CASH FLOWS

  2023  2022 
  Three Months ended June 30, 
  2023  2022 
       
Cash flows from operating activities:        
Net loss $(29,727) $(21,105)
Adjustments to reconcile net income (loss) to net cash used in operating activities:        
Depreciation  78   79 
Changes in operating assets and liabilities:        
Prepaid expense  (738)  - 
Accrued liabilities  3,401   8,596 
Contract liabilities  (1,200)  (2,400)
Net cash used in operating activities  (28,186)  (14,830)
         
Cash flows from financing activities:        
Proceeds from shareholder loan  62,156   2,000 
Net cash provided by financing activities  62,156   2,000 
         
Net increase (decrease) in cash and cash equivalents  33,970   (12,830)
         
Cash and cash equivalents, beginning balance  354   14,269 
Cash and cash equivalents, ending balance $34,324  $1,439 
         
SUPPLEMENTARY DISCLOSURE:        
         
Interest paid $-  $- 
Income tax paid $-  $- 
         

SUPPLEMENTARY DISCLOSURE OF NON-CASH INVESTMENT AND FINANCING ACTIVITIES:

        
         
Related party debt forgiven as additional paid-in capital $83,300  $- 

The accompanying notes are an integral part of these financial statements

8

 

ANTIAGING QUANTUM LIVING INC (FKA. ACHISON INCINC)

NOTES TO THE UNAUDITED FINANCIAL STATEMENTS

 

NOTE 1 – ORGANIZATION AND PRINCIPAL ACTIVITIES

Antiaging Quantum Living Inc. (FKA: Achison Inc.) (the “Company”, “us”, “we” or “our”) was incorporated under the laws of the State of New York on December 29, 2014.

On July 1, 2019, Lansdale Inc, the principal stockholder of the Company (“Seller”) and controlled by the Company’s priorformer President, Mr. Wanjun Xie, entered into a Stock Purchase Agreement (the “Agreement”) with Dazhong 368 Inc, (the “Buyer”), pursuant to which, a total of 9,000,000 shares of Class A common stock of the Company were transferred to the Buyer, representing approximately 90% of the Company’s issued and outstanding shares of Class A common stock, resulting in a change of the control of the Company. Mr. Dingshan Zhang was appointed as the President and CEO of the Company at the same date.

Prior to July of 2019 the Company primarily engaged in trading spot gold and silver in Singapore Markets, crypto currency and US equity stocks. The Company currently engages only in internet advertising through www.dazhong368.com (the “Website”) in the New York areaarea.

On April 10, 2023, Mr. Barry Wan acquired control of 29,215,000 restricted shares of common stock (the “Purchased Shares”) of the Company, representing approximately 97% of the Company’s total issued and has plansoutstanding common stock (the “Common Stock”) from Dazhong 368 Inc and Sophia 33 Inc, two New York corporations controlled by the Company’s then President, Chief Executive Officer and sole director, Dingshan Zhang (the former President) pursuant to seek other profitablethe terms of a Stock Purchase Agreement by and among the parties thereto (the “Stock Purchase Agreement”). Pursuant to the Stock Purchase Agreement (“SPA”), Mr. Wan paid an aggregate purchase price of four hundred thousand dollars ($400,000.00) to Mr. Zhang in exchange for the Purchased Shares. The foregoing transaction resulted in a change of control of the Company, with Mr. Wan acquiring 97% of the Company’s outstanding Common Stock held through New Lite Ventures LLC, a New York LLC. Both before and after the transactions, the Company had 29,995,000 shares of its common stock outstanding.

In connection with the transaction, on April 10, 2023, Mr. Dingshan Zhang resigned from all positions he held with the Company. On April 10, 2023, Ms. Jing Wan was appointed by our majority shareholder as our Chief Executive Officer, Chief Financial Officer, President and Director. On June 16, 2023, Mr. Barry Wan consented to act as the new CEO and CFO after Ms. Jing Wan resigned. The Company was renamed as Antiaging Quantum Living Inc on June 14, 2023 by the new management.

The change in control with respect to the Company is to better reflect its new business atdirection, with the same time.intention of acquiring businesses involved in healthcare management and insurance services.

 

NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

 

Basis of Presentation

In the opinion of management, the unaudited interim condensed financial statements reflect all adjustments of a normal recurring nature that are necessary for a fair presentation of the results for the interim periods presented. However, the results of operations included in such financial statements may not necessary be indicative of annual results.

The Company uses the same accounting policies in preparing quarterly and annual financial statements. Certain information and footnote disclosures normally included in the annual financial statements prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) have been condensed or omitted. These unaudited condensed financial statements should be read in conjunction with the Company’s audited financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the year ended March 31, 20222023 filed with the Securities and Exchange Commission (“SEC”) on June 28, 2022July 14, 2023 (“20212023 Form 10-K.”)

9

 

Use of Estimates

 

The accompanying financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) and the rules and regulations of the Securities and Exchange Commission (the “SEC”).

 

The preparation of the Company’s financial statements in conformity with GAAP requires management to make estimates, judgments and assumptions that affect the amounts reported in the financial statements and footnotes thereto. Actual results may differ from those estimates and assumptions.

 

Cash and Cash Equivalents

 

Cash and cash equivalents include cash in banks, bank deposits, and highly liquid investments with maturities of three months or less at the date of origination.

 

Intangible assets, net

The Company’s intangible asset with definite useful lives consists of a website. The Company typically amortizes its intangible asset with definite useful lives on a straight-line basis over the shorter of the contractual terms or the estimated useful lives. The Company estimate the useful lives of the website is 10 years.

The website - www.Dazhong368.com (the “Website”) was acquired from entities under common control by issuing 10 million shares of Class A common stock in September 2019, and the zero carry value of the website at the related party’s book was transferred for the assets purchase. As of September 30, 2022 and March 31, 2022, the Company had nil intangible assets.

Impairment of Long-Lived and Intangible Assets

Management reviews long-lived assets and certain identifiable intangible assets with finite lives for impairment in accordance with Accounting Standards Codification (“ASC”) 360, “Property, Plant, and Equipment.” Goodwill and intangible assets not subject to amortization are reviewed annually for impairment in accordance with ASC 350, “Intangibles — Goodwill and Other,” or more often if there are indications of possible impairment.

9

The analysis to determine whether or not an asset is impaired requires significant judgment that is dependent on internal forecasts, including estimated future cash flows, estimates of long-term growth rates for our business, the expected life over which cash flows will be realized and assumed royalty and discount rates. Changes in these estimates and assumptions could materially affect the determination of fair value and any impairment charge. While the fair value of these assets exceeds their carrying value based on management’s current estimates and assumptions, materially different estimates and assumptions in the future in response to changing economic conditions, changes in the business, increased competition or loss of market share, product innovation or obsolescence, product claims that result in a significant loss of sales or profitability over the product life or for other reasons could result in the recognition of impairment losses.

Revenue Recognition

 

Revenue is recognized when control of the promised goods or services is transferred to our customers, in an amount that reflects the consideration we expect to be entitled to in exchange for those goods or services. The Company determines revenue recognition by applying the following steps: 1) identification of the contract, or contracts, with a customer; 2) identification of the performance obligations in the contract; 3) determination of the transaction price; 4) allocation of the transaction price to the performance obligations in the contract; and 5) recognition of revenue when, or as, we satisfy a performance obligation.

 

Advertising revenue is generated by displaying advertising products on the Website.our website. The Company recognizes revenue from the display of impression-based advertisements in the contracted period in which the impressions are delivered.displayed. Impressions are considered delivered when an advertisement is displayed to users.the Website visitors. In general, the Company presents advertising revenue on a gross basis, since the Company controls the advertising inventory before it is transferred to its customers. Control of advertisement inventory is evidenced by the Company’s sole ability to monetize the advertising inventory before it is transferred to our customers. Pricing for our services is generally a fixed amount at a monthly level and is typically due within 30 days upon signing the contract with customers. Unsatisfied performance obligations under advertising contracts are recorded as contract liabilities.

10

 

Income Taxes

 

The Company records income tax expense using the asset-and-liability method of accounting for deferred income taxes. Under this method, deferred taxes are recognized for the tax consequences in future years of differences between the tax bases of assets and liabilities and their financial reporting amounts at each year-end based on enacted tax laws and statutory tax rates applicable to the periods in which the differences are expected to affect taxable income. Deferred tax assets are reduced by a valuation allowance if, based on available evidence, it is more likely than not that the deferred tax assets will not be realized.

 

When tax returns are filed, it is likely some positions taken would be sustained upon examination by the taxing authorities, while others are subject to uncertainty about the merits of the position taken or the amount of the position that would be ultimately sustained. The benefit of a tax position is recognized in the financial statements in the period during which, based on all available evidence, management believes it is more-likely-than-not the position will be sustained upon examination, including the resolution of appeals or litigation processes, if any. Tax positions taken are not offset or aggregated with other positions. Tax positions that meet the more-likely-than-not recognition threshold are measured as the largest amount of tax benefit that is more than 50% likely of being realized upon settlement with the applicable taxing authority. The portion of the benefits associated with tax positions taken that exceeds the amount described above is reflected as a liability for unrecognized tax benefits in the accompanying balance sheets along with any associated interest and penalties that would be payable to the taxing authorities upon examination. Interest associated with unrecognized tax benefits is classified as interest expense and penalties are classified in general and administrative expenses in the statements of operations.

10

 

Earnings Per Share

 

The Company computes basic and diluted earnings per share amounts in accordance with ASC Topic 260, Earnings per Share. Basic earnings per share is computed by dividing net income (loss) available to common shareholders by the weighted average number of common shares outstanding during the reporting period. Diluted earnings per share reflects the potential dilution that could occur if stock options and other commitments to issue common stock were exercised or equity awards vest resulting in the issuance of common stock that could share in the earnings of the Company.

 

As of SeptemberJune 30, 20222023 and March 31, 2022,2023, the Company does not have any potentially dilutive instrument.

 

Contingencies

 

Certain conditions may exist as of the date the financial statements are issued, which could result in a loss to the Company which will be resolved when one or more future events occur or fail to occur. The Company’s management assesses such contingent liabilities, and such assessment inherently involves judgment. In assessing loss contingencies arising from legal proceedings pending against the Company or unasserted claims that may rise from such proceedings, the Company’s management evaluates the perceived merits of any legal proceedings or unasserted claims as well as the perceived merits of the amount of relief sought or expected to be sought.

 

If the assessment of a contingency indicates it is probable a material loss will be incurred and the amount of the loss can be reasonably estimated, then the estimated loss is accrued in the Company’s financial statements. If the assessment indicates a material loss contingency is not probable but is reasonably possible, or is probable but cannot be estimated, then the nature of the contingent liability, together with an estimate of the range of possible loss if determinable and material would be disclosed.

 

Fair Value Measurements

 

Fair value accounting establishes a framework for measuring fair value and expands disclosure about fair value measurements. Fair value, which is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. This framework provides a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into three levels as follows:

 

 Level 1 inputs to the valuation methodology are quoted prices (unadjusted) for identical assets or liabilities in active markets.

 Level 2 inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, and inputs that are observable for the assets or liabilities, either directly or indirectly, for substantially the full term of the financial instruments.

 Level 3 inputs to the valuation methodology are unobservable and significant to the fair value.

 

The Company’s financial instruments consisted of cash, accounts payable, contract liabilityliabilities and loan from a shareholder.shareholders. The estimated fair value of those balances approximate itsapproximates the carrying amount due to the short maturity of these instruments.

 

Accounting Standards Issued but Not Yet Adopted

11

 

Credit LossesRecent Accounting Pronouncements

In June 2016, the FASB issued ASU No. 2016-13, (Topic 326), Financial Instruments – Credit Losses: Measurement of Credit Losses on Financial Instruments which amends the current accounting guidance and requires the use of the new forward-looking “expected loss” model, rather than the “incurred loss” model, which requires all expected losses to be determined based on historical experience, current conditions and reasonable and supportable forecasts. This guidance amends the accounting for credit losses for most financial assets and certain other instruments including trade and other receivables, held-to-maturity debt securities, loans and other instruments.

11

In November 2019, the FASB issued ASU No. 2019-10 to postpone the effective date of ASU No. 2016-13 for public business entities eligible to be smaller reporting companies (SRCs) as defined by the SEC. ASU No. 2016-13 is effective for SRCs for fiscal years beginning after December 15, 2022, including interim periods within those fiscal years. The Company is evaluating the impact of the adoption ofadopted ASU 2016-13 on its financial position and results of operations.operations as of April 1, 2023, with no material impact.

 

There were other updates recently issued. The management does not believe that other than the disclosed above, accounting pronouncements the recently issued but not yet adopted will have a material impact on its financial position results of operations or cash flows.

 

NOTE 3 – GOING CONCERN

 

The Company’s financial statements have been prepared on a going concern basis, which contemplates the realization of assets and settlement of liabilities and commitments in the normal course of business. During the six months ended September 30, 2022, the Company incurred a net loss of $22,625. The Company had an accumulated deficit of $262,327306,059 as of SeptemberJune 30, 20222023 and negative working capital of $72,79932,996. These factors, among others, raise substantial doubt about the Company’s ability to continue as a going concern.

 

Management’s plan to alleviate the substantial doubt about the Company’s ability to continue as a going concern include attempting to improve its business profitability, its ability to generate sufficient cash flow from its operations to meet its operating needs on a timely basis, obtain additional working capital funds from the majority shareholder and President of the Company to eliminate inefficiencies in order to meet its anticipated cash requirements. However, there can be no assurance that these plans and arrangements will be sufficient to fund the Company’s ongoing capital expenditures and other requirements.

 

The financial statements do not include any adjustments relating to the recoverability and classification of recorded assets, or the amounts and classification of liabilities that might be necessary in the event that the Company cannot continue as a going concern.

12

 

NOTE 4 – RELATED PARTY TRANSACTIONS

 

Lease

 

The Company has been provided office space by its President at no cost. The management determined that such cost is immaterial and did not recognize the rent expense in its financial statements.

 

Loan from shareholders

 

In August 2019, the Company borrowed $71,000 from the former President of the Company, which bears no interest with a maturity in December 2021. During the year ended March 31, 2022, the Company repaid $17,000 to the former President of the Company after the Company borrowed $5,000 in May 2021. On December 29, 2022 and 2021, the Company and our former President entered intoverbally amended the first amendment toloan agreement and extend the maturity date to December 31, 20222023. During the year ended March 31, 2023, the Company received additional loan of $24,300 from its former President, Mr. Dingshan Zhang. Upon consummated the change of control resulted from the SPA entered on April 10, 2023, $83,300 shareholder loan was waived by Mr. Zhang in its entirety, which was recognized as an equity transaction with the shareholder.

 

FromDuring the three months ended June to August30, 2022, the Company borrowedreceived advances in the total amount of $11,90062,156 in aggregate from theour President of the Company, which bears no interestfor working capital purpose. The loan is unsecured, non-interest-bearing and is due on demand.

As of September 30, 2022 and March 31, 2022, the outstanding balance of shareholder loan was $70,900 and $59,000, respectively.

 

NOTE 5 – CONTRACT LIABILITIES

 

Contract liabilities includerepresent payments received in advance of performance under the contract for the unsatisfied performance obligation and are realized when the associated revenue is recognized under the contract.advertising contracts. As of SeptemberJune 30, 20222023 and March 31, 2022,2023, contract liabilities were $3,2001,600 and $5,6002,800, respectively.

12

NOTE 6 – INCOME TAX

 

The Company has not recognized an income tax benefit for its operating losses generated based on uncertainties concerning its ability to generate taxable income in future periods. The tax benefit for the period presented is offset by a valuation allowance established against deferred tax assets arising from the net operating losses, the realization of which could not be considered more likely than not. In future periods, tax benefits and related deferred tax assets will be recognized when management considers realization of such amounts to be more likely than not.

 

For the six months ended September 30, 2022 and the year ended March 31, 2022, the Company has incurred a net loss before tax of $22,625 and $43,436, respectively. Net operation losses (“NOLs”) can be carried forever based on the 2017 Tax Cuts and Jobs Act. As of SeptemberJune 30, 20222023 and March 31, 2022,2023, deferred tax assets resulted from NOLs of approximately $37,63754,000 and $31,32369,000, which was fully off-set by valuation allowance reserved.

NOTE 7 – SHAREHOLDERS’ EQUITY

The Company is authorized to issued 30,000,000 shares of Class A common stock.

On August 19, 2019, the Company amended its article with New York State to increase the authorized Class A common shares with a par value of $0.001 to 30,000,000 shares.

On October 11, 2021, the Company amended its article with New York State to change the authorized Class A common shares with a par value of $0.001 to 100,000,000 shares; and to increase the authorized preferred shares with par value $0.001 to 20,000,000 shares.

On March 28, 2023, the Company amended its article with New York State to change the authorized common shares with a par value of $0.001 to 30,000,000 shares, no preferred shares.

During the three months ended June 30, 2023, shareholder loan of $83,300 was forgiven by our former President and recorded as additional paid-in capital.

 

NOTE 78SUBSEQUENT EVENTS

 

The Company evaluated all events or transactions that occurred after SeptemberJune 30, 20222023 through the date the financial statements were available to be issued. During the period, the Company did not have any material recognizable subsequent events required to be disclosed or adjusted as of and for the sixthree months ended SeptemberJune 30, 2022.2023.

 

13

MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITIONS AND RESULTS OF OPERATIONS.Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

 

This Quarterly Report on Form 10-Q contains forward-looking statements, particularly those identified with the words, “anticipates,” “believes,” “expects,” “plans,” “intends,” “objectives,” and similar expressions. These statements reflect management’s best judgment based on factors known at the time of such statements. The reader may find discussions containing such forward-looking statements in the material set forth under “Management’s Discussion and Analysis of Financial Condition and Results of Operations”Operations,” generally, and specifically therein under the captions “Liquidity and Capital Resources” as well as elsewhere in this Quarterly Report on Form 10-Q. Actual events or results may differ materially from those discussed herein. The forward-looking statements specified in the following information have been compiled by our management on the basis of assumptions made by management and considered by management to be reasonable. Our future operating results, however, are impossible to predict and no representation, guarantee, or warranty is to be inferred from those forward-looking statements. The assumptions used for purposes of the forward-looking statements specified in the following information represent estimates of future events and are subject to uncertainty as to possible changes in economic, legislative, industry, and other circumstances. As a result, the identification and interpretation of data and other information and their use in developing and selecting assumptions from and among reasonable alternatives require the exercise of judgment. To the extent that the assumed events do not occur, the outcome may vary substantially from anticipated or projected results, and, accordingly, no opinion is expressed on the achievability of those forward-looking statements. No assurance can be given that any of the assumptions relating to the forward-looking statements specified in the following information are accurate, and we assume no obligation to update any such forward-looking statements.

 

Overview

 

Antiaging Quantum Living Inc. (FKA: Achison Inc.) (the “Company”, “us”, “we” or “our”) was incorporated under the laws of the State of New York on December 29, 2014.

 

On July 1, 2019, Lansdale Inc, the principal stockholder of the Company (“Seller”) and controlled by the Company’s priorformer President, Mr. Wanjun Xie, entered into a Stock Purchase Agreement (the “Agreement”) with Dazhong 368 Inc, (the “Buyer”), pursuant to which, a total of 9,000,000 shares of Class A common stock of the Company were transferred to the Buyer, representing approximately 90% of the Company’s issued and outstanding shares of Class A common stock, on July 1, 2019 which also resultsresulting in a change of the control of the Company. Mr. Dingshan Zhang was appointed as the President and CEO of the Company at the same date.

14

Prior to July of 2019 the Company primarily engaged in trading spot gold and silver in Singapore Markets, crypto currency and US equity stocks. Currently, the The Company currently engages only in internet advertising through www.dazhong368.com (the “Website”) in the New York areaarea.

On April 10, 2023, Mr. Barry Wan acquired control of 29,215,000 restricted shares of common stock (the “Purchased Shares”) of the Company, representing approximately 97% of the Company’s total issued and has plansoutstanding common stock (the “Common Stock”) from Dazhong 368 Inc and Sophia 33 Inc, two New York corporations controlled by the Company’s then President, Chief Executive Officer and sole director, Dingshan Zhang (the former President) pursuant to seek other profitablethe terms of a Stock Purchase Agreement by and among the parties thereto (the “Stock Purchase Agreement”). Pursuant to the Stock Purchase Agreement (“SPA”), Mr. Wan paid an aggregate purchase price of four hundred thousand dollars ($400,000.00) to Mr. Zhang in exchange for the Purchased Shares. The foregoing transaction resulted in a change of control of the Company, with Mr. Wan acquiring 97% of the Company’s outstanding Common Stock held through New Lite Ventures LLC, a New York LLC. Both before and after the transactions, the Company had 29,995,000 shares of its common stock outstanding.

In connection with the transaction, on April 10, 2023, Mr. Dingshan Zhang resigned from all positions he held with the Company. On April 10, 2023, Ms. Jing Wan was appointed by our majority shareholder as our Chief Executive Officer, Chief Financial Officer, President and Director. On June 16, 2023, Mr. Barry Wan consented to act as the new CEO and CFO after Ms. Jing Wan resigned. The Company was renamed as Antiaging Quantum Living Inc on June 14, 2023 by the new management.

The change in control with respect to the Company is to better reflect its new business atdirection, with the same time.intention of acquiring businesses involved in healthcare management and insurance services.

 

Results of Operation for the three months ended SeptemberJune 30, 20222023 and 20212022

 

During the three months ended SeptemberJune 30, 20222023 and 2021,2022, the Company generated revenue in the amount of $6,000$1,200 and $1,800,$2,400, respectively. During the three months ended June 30, 2023 and 2022, the Company incurred operating expenses of $30,927 and $23,505, respectively. The increase was mainly due to our growing online advertising business formally launchedthe increase in the second half of year 2020. During the three months ended September 30, 2022 and 2021, the Company incurred operating expenses of $7,520 and $8,832, respectively. The decrease was mainly due to the decreasing in professional fees.donation expense. For the three months ended SeptemberJune 30, 2022 and 2021,2023, our net loss was ($1,520) and ($6,931), respectively. The decrease in$29,727 comparing to a net loss was mainly due to the increase in our total revenues together with the decrease in our total operating expensesof $21,105 for the three months ended SeptemberJune 30, 2022 compared to 2021.

Results of Operation for the six months ended September 30, 2022 and 2021

During the six months ended September 30, 2022 and 2021, the Company generated revenue in the amount of $8,400 and $3,600, respectively. The increase was mainly due to our growing online advertising business formally launched in the second half of year 2020. During the six months ended September 30, 2022 and 2021, the Company incurred operating expenses of $31,025 and $25,043, respectively. The increase of operating expenses was mainly due to the increasing in the professional fees. For the six months ended September 30, 2022 and 2021, our net loss was $22,625 and $20,469, respectively.2022. The increase in net loss wasis mainly due to the increase inincreased operating expenses for the six months ended September 30, 2022, compared to 2021, partially offset by the increase of our total revenues.expenses.

 

Equity and Capital Resources

 

As of SeptemberJune 30, 2022,2023, we had an accumulated deficit of $262,327.$306,059. As of SeptemberJune 30, 2022,2023, we had cash of $1,301$34,324 and negative working capital of $72,799,$32,996, compared to cash of $14,269$354 and a negative working capital of $50,331 on$86,647 as of March 31, 2022.2023. The decreaseincrease in the working capital was primarily due to advances from the Present and the loan forgiveness by the former President which was partially offset by cash used to pay for operating expenses. These factors and our ability to raise additional capital to accomplish our objectives, raises substantial doubt about our ability to continue as a going concern.

14

 

Going Concern Assessment

 

The Company demonstrates adverse conditions that raise substantial doubt about the Company’s ability to continue as a going concern. These adverse conditions are negative financial trends, specifically cash outflow from operating activities, operating losses, accumulated deficit and other adverse key financial ratios.

 

Management’s plan to alleviate the substantial doubt about the Company’s ability to continue as a going concern include attempting to improve its business profitability, its ability to generate sufficient cash flow from its operations to meet its operating needs on a timely basis, obtain additional working capital funds from the majority shareholder and the President of the Company to eliminate inefficiencies in order to meet its anticipated cash requirements. However, there can be no assurance that these plans and arrangements will be sufficient to fund the Company’s ongoing capital expenditures and other requirements.

 

The unaudited condensed financial statements do not include any adjustments relating to the recoverability and classification of recorded assets, or the amounts and classification of liabilities that might be necessary in the event that the Company cannot continue as a going concern.

15

 

Off-Balance Sheet Arrangements

 

We have no off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that is material to stockholders.

 

Critical Accounting Policies

 

The financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States. The preparation of these financial statements requires making estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. The estimates are based on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis of making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.

 

The critical accounting policies are discussed in further detail in the notes to the unaudited financial statements appearing elsewhere in this 10-Q report. Management believes that the application of these policies on a consistent basis enables us to provide useful and reliable financial information about our operating results and financial condition.condition

 

Item 3. Quantitative and Qualitative Disclosures About Market Risk

 

As a “small“smaller reporting company” we are not required to provide this information under this item pursuant to Regulation S-K.

15

 

Item 4. Controls and Procedures.

 

Evaluation of Disclosure Controls and Procedures

 

Disclosure controls and procedures are designed with an objective of ensuring that information required to be disclosed in our periodic reports filed with the Securities and Exchange Commission, such as this Quarterly Report on Form 10-Q, is recorded, processed, summarized and reported within the time periods specified by the Securities and Exchange Commission. Disclosure controls are also designed with an objective of ensuring that such information is accumulated and communicated to our management, including our chief executive officer, in order to allow timely consideration regarding required disclosures.

 

The evaluation of our disclosure controls by our principal executive officer included a review of the controls’ objectives and design, the operation of the controls, and the effect of the controls on the information presented in this Annual Report. Our management, including our Chief Executive Officer, does not expect that disclosure controls can or will prevent or detect all errors and all fraud, if any. A control system, no matter how well designed and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Also, projections of any evaluation of the disclosure controls and procedures to future periods are subject to the risk that the disclosure controls and procedures may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

 

As of the end of the period covered by this report, we carried out an evaluation, under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, of the effectiveness of our disclosure controls and procedures, as defined in Rules 13a-15(e) and 15d-15(e) of the Securities Exchange Act of 1934 as of the end of the period covered by this report. Based on that evaluation, our Chief Executive Officer and Chief Financial Officer have concluded that there were material weakness in our internal controls over Financial reporting as of SeptemberJune 30, 20222023 and they were therefore not as effective as they could be to ensure that information required to be disclosed by us in reports that we file or submit under the Securities Exchange Act of 1934 is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission’s rules and forms. The material weakness in our controls and procedure were lack of US GAAP knowledge and segregation duties. Management does not believe that any of these material weaknesses materially affected the results and accuracy of its financial statements. However, in view of this discovery of such weaknesses, management has begun a review to improve them.

Changes in Internal Control over Financial Reporting

 

There were no changes in our internal control over financial reporting identified in connection with the evaluation required by paragraph (d) of Rule 13a-15 or Rule 15d-15 under the Exchange Act that occurred during the quarter ended SeptemberJune 30, 20222023 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

16

PART II – OTHER INFORMATION

 

Item 1. Legal Proceedings.

 

None

 

Item 1A. Risk Factors.

 

As a “smaller reporting company”, we are not required to provide this information under this item pursuant to Regulation S-K.

 

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

 

None

 

Item 3. Defaults Upon Senior Securities

 

None

 

Item 4. Mine Safety Disclosures

 

Not applicable.

 

Item 5. Other Information

 

None

16

 

Item 6. Exhibits

 

Exhibit

Number

Description of Exhibit
31.1*Certification of Chief Executive Officer pursuant to the Securities Exchange Act Rules 13a-14(a) and 15d-14(a)
  
31.2*Certification of Chief Financial Officer pursuant to the Securities Exchange Act Rules 13a-14(a) and 15d-14(a)
  
32.1*Certification of Chief Executive Officer and Chief Financial Officer pursuant to 18 U.S.C. Section 1350
  
101.INSInline XBRL Instance Document
  
101.SCHInline XBRL Taxonomy Extension Schema Document
  
101.CALInline XBRL Taxonomy Extension Calculation Linkbase Document
  
101.DEFInline XBRL Taxonomy Extension Definition Linkbase Document
  
101.LABInline XBRL Taxonomy Extension Label Linkbase Document
  
101.PREInline XBRL Taxonomy Extension Presentation Linkbase Document

104Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

* Filed herewith.

 

17

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

 

ACHISONANTIAGING QUANTUM LIVING INC

Date: August 18, 2023/s/ Barry Wan
Barry Wan, Chief Executive Officer
  
Date: November 14, 2022August 18, 2023/s/ Dingshan ZhangBarry Wan
 Dingshan Zhang, President
(Principal Executive Officer)
Date: November 14, 2022/s/ Dingshan Zhang
Dingshan Zhang,Barry Wan, Chief Financial Officer
(Principal Financial and Accounting Officer)

 

18

 

EXHIBIT INDEX

 

Exhibit

Number

Description of Exhibit
31.1*Certification of Chief Executive Officer pursuant to the Securities Exchange Act Rules 13a-14(a) and 15d-14(a)
  
31.2*Certification of Chief Financial Officer pursuant to the Securities Exchange Act Rules 13a-14(a) and 15d-14(a)
  
32.1*Certification of Chief Executive Officer and Chief Financial Officer pursuant to 18 U.S.C. Section 1350
  
101.INSInline XBRL Instance Document
  
101.SCHInline XBRL Taxonomy Extension Schema Document
  
101.CALInline XBRL Taxonomy Extension Calculation Linkbase Document
  
101.DEFInline XBRL Taxonomy Extension Definition Linkbase Document
  
101.LABInline XBRL Taxonomy Extension Label Linkbase Document
  
101.PREInline XBRL Taxonomy Extension Presentation Linkbase Document

104Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

* Filed herewith.

 

19